Representing Lantronix’s Global and Diverse Partner Ecosystem, SmartEdge Winners Deliver Lantronix’s Award-Winning Solutions to the World IRVINE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) — Lantronix Inc. (NASDAQ: LTRX), a global leader of compute and connectivity IoT solutions, today announced the winners of its 2024 SmartEdge™ Partner Program Awards, highlighting its
Fraud and Security solution is acknowledged for its unique features and integration of advanced AI technologies LONDON, Sept. 04, 2024 (GLOBE NEWSWIRE) — Quantexa, the global leader in Decision Intelligence (DI) solutions for the public and private sectors, today announced that its Fraud Detection solution has been awarded “Luminary” status
Fraud and Security solution is acknowledged for its unique features and integration of advanced AI technologies LONDON, Sept. 04, 2024 (GLOBE NEWSWIRE) — Quantexa, the global leader in Decision Intelligence (DI) solutions for the public and private sectors, today announced that its Fraud Detection solution has been awarded “Luminary” status
Setting new standards for the projector industry with epic brightness, contrast, and color reproduction—achieved all at once JMGO Set to Ace Laser Projection with MALC™ 2.0 Triple Laser Optics at IFA 2024 BERLIN, Sept. 04, 2024 (GLOBE NEWSWIRE) — JMGO, a pioneer in optical technology, will showcase its in-house developed
Acquisition Adds Electric Motor, Generator, Mechanical, Switchgear & Circuit Breaker Service Centers to IPS’s Growing North American Network IPS President and CEO John Zuleger GREENVILLE, S.C., Sept. 03, 2024 (GLOBE NEWSWIRE) — Integrated Power Services (IPS), a North American leader in the servicing, engineering, and remanufacturing of electrical, mechanical, and
NAPLES, Fla., Sept. 03, 2024 (GLOBE NEWSWIRE) — Music Licensing, Inc. (OTC: SONG), a leading entity in the music industry, is excited to announce the acquisition of the royalty rights to “Thank God I Got It” by the renowned artist Desiigner. This acquisition underscores Music Licensing, Inc.’s commitment to diversifying
REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for the potential treatment of symptomatic CCM in subsequent studies. SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage
Nyxoah Rings the Closing Bell at Nasdaq while Preparing for U.S. Market Launch of Innovative Sleep Apnea Device FDA regulatory submission for the Company’s Genio® device is complete, U.S. approval on track for the end of 2024 U.S. commercial launch, expected at the beginning of 2025, fully funded with over